Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer

Research output: Contribution to journalReview article

Abstract

Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in non-small cell lung cancer (NSCLC) and have each demonstrated improvements in outcomes and quality of life when compared to chemotherapy. Enrichment strategies to better select those patients more likely to respond have identified PD-L1 staining by immunohistochemistry (IHC) to be a predictive biomarker in both treatment naïve and refractory patients. Unfortunately, many challenges exist with this strategy and underscore the need for further exploration for more reliable biomarkers. Multiple tissue and plasma-based enrichment strategies have been identified in the hope of identifying patients more likely to benefit from checkpoint inhibitors. These include tumor mutational load; the "inflamed phenotype" including tumor infiltrating lymphocytes (TILS) and immunoscore; T-cell receptor clonality; gene signatures, and several plasma biomarkers. Several studies have revealed many of these biomarkers to be reliable predictors of response to immune checkpoint inhibitors across multiple tumor types. Given the small nature of these studies, additional prospective studies are warranted to formalize and validate each of these enrichment strategies.

Original languageEnglish (US)
Article number376
JournalAnnals of Translational Medicine
Volume5
Issue number18
DOIs
StatePublished - Sep 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Biomarkers
Tumor Escape
Tumor-Infiltrating Lymphocytes
T-Cell Antigen Receptor
Allergy and Immunology
Tumor Burden
Neoplasms
Immunohistochemistry
Quality of Life
Prospective Studies
Staining and Labeling
Ligands
Phenotype
Drug Therapy
Antibodies
Therapeutics
Genes

Keywords

  • Biomarkers
  • Immunotherapy
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. / Voong, Khinh; Feliciano, Josephine; Becker, Daniel; Levy, Benjamin.

In: Annals of Translational Medicine, Vol. 5, No. 18, 376, 01.09.2017.

Research output: Contribution to journalReview article

@article{097778047b5d4902ac035681cecdc854,
title = "Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer",
abstract = "Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in non-small cell lung cancer (NSCLC) and have each demonstrated improvements in outcomes and quality of life when compared to chemotherapy. Enrichment strategies to better select those patients more likely to respond have identified PD-L1 staining by immunohistochemistry (IHC) to be a predictive biomarker in both treatment na{\"i}ve and refractory patients. Unfortunately, many challenges exist with this strategy and underscore the need for further exploration for more reliable biomarkers. Multiple tissue and plasma-based enrichment strategies have been identified in the hope of identifying patients more likely to benefit from checkpoint inhibitors. These include tumor mutational load; the {"}inflamed phenotype{"} including tumor infiltrating lymphocytes (TILS) and immunoscore; T-cell receptor clonality; gene signatures, and several plasma biomarkers. Several studies have revealed many of these biomarkers to be reliable predictors of response to immune checkpoint inhibitors across multiple tumor types. Given the small nature of these studies, additional prospective studies are warranted to formalize and validate each of these enrichment strategies.",
keywords = "Biomarkers, Immunotherapy, Non-small cell lung cancer (NSCLC)",
author = "Khinh Voong and Josephine Feliciano and Daniel Becker and Benjamin Levy",
year = "2017",
month = "9",
day = "1",
doi = "10.21037/atm.2017.06.48",
language = "English (US)",
volume = "5",
journal = "Annals of Translational Medicine",
issn = "2305-5839",
publisher = "AME Publishing Company",
number = "18",

}

TY - JOUR

T1 - Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer

AU - Voong, Khinh

AU - Feliciano, Josephine

AU - Becker, Daniel

AU - Levy, Benjamin

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in non-small cell lung cancer (NSCLC) and have each demonstrated improvements in outcomes and quality of life when compared to chemotherapy. Enrichment strategies to better select those patients more likely to respond have identified PD-L1 staining by immunohistochemistry (IHC) to be a predictive biomarker in both treatment naïve and refractory patients. Unfortunately, many challenges exist with this strategy and underscore the need for further exploration for more reliable biomarkers. Multiple tissue and plasma-based enrichment strategies have been identified in the hope of identifying patients more likely to benefit from checkpoint inhibitors. These include tumor mutational load; the "inflamed phenotype" including tumor infiltrating lymphocytes (TILS) and immunoscore; T-cell receptor clonality; gene signatures, and several plasma biomarkers. Several studies have revealed many of these biomarkers to be reliable predictors of response to immune checkpoint inhibitors across multiple tumor types. Given the small nature of these studies, additional prospective studies are warranted to formalize and validate each of these enrichment strategies.

AB - Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in non-small cell lung cancer (NSCLC) and have each demonstrated improvements in outcomes and quality of life when compared to chemotherapy. Enrichment strategies to better select those patients more likely to respond have identified PD-L1 staining by immunohistochemistry (IHC) to be a predictive biomarker in both treatment naïve and refractory patients. Unfortunately, many challenges exist with this strategy and underscore the need for further exploration for more reliable biomarkers. Multiple tissue and plasma-based enrichment strategies have been identified in the hope of identifying patients more likely to benefit from checkpoint inhibitors. These include tumor mutational load; the "inflamed phenotype" including tumor infiltrating lymphocytes (TILS) and immunoscore; T-cell receptor clonality; gene signatures, and several plasma biomarkers. Several studies have revealed many of these biomarkers to be reliable predictors of response to immune checkpoint inhibitors across multiple tumor types. Given the small nature of these studies, additional prospective studies are warranted to formalize and validate each of these enrichment strategies.

KW - Biomarkers

KW - Immunotherapy

KW - Non-small cell lung cancer (NSCLC)

UR - http://www.scopus.com/inward/record.url?scp=85029700939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029700939&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.06.48

DO - 10.21037/atm.2017.06.48

M3 - Review article

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

IS - 18

M1 - 376

ER -